These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 25545248)

  • 21. Challenges and perspectives in anti-doping testing.
    Schamasch P; Rabin O
    Bioanalysis; 2012 Jul; 4(13):1691-701. PubMed ID: 22831484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Athlete Biological Passport: an integral element of innovative strategies in antidoping.
    Vernec AR
    Br J Sports Med; 2014 May; 48(10):817-9. PubMed ID: 24659508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Annual banned-substance review 16
    Thevis M; Kuuranne T; Geyer H
    Drug Test Anal; 2024 Jan; 16(1):5-29. PubMed ID: 37985429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigating the use of stimulants in out-of-competition sport samples.
    Boghosian T; Mazzoni I; Barroso O; Rabin O
    J Anal Toxicol; 2011 Nov; 35(9):613-6. PubMed ID: 22080900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting prohibited substances in doping control blood samples by means of chromatographic-mass spectrometric methods.
    Thevis M; Thomas A; Schänzer W
    Anal Bioanal Chem; 2013 Dec; 405(30):9655-67. PubMed ID: 23925796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of the COVID-19 pandemic on the use of the performance-enhancing drugs.
    Negro F; Di Trana A; Marinelli S
    Acta Biomed; 2022 Jan; 92(6):e2021401. PubMed ID: 35075058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analytical progresses of the World Anti-Doping Agency Olympic laboratories: a 2016 update from London to Rio.
    Athanasiadou I; Voss S; Lyris E; Aljaber A; Alsayrafi M; Georgakopoulos C
    Bioanalysis; 2016 Nov; 8(21):2265-2279. PubMed ID: 27665839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An anti-doping sampling strategy utilizing the sewerage systems of sport villages.
    Katsoyiannis A; Jones KC
    Environ Sci Technol; 2011 Jan; 45(2):362-3. PubMed ID: 21142144
    [No Abstract]   [Full Text] [Related]  

  • 29. The analytical chemistry of drug monitoring in athletes.
    Bowers LD
    Annu Rev Anal Chem (Palo Alto Calif); 2009; 2():485-507. PubMed ID: 20636072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anabolic agents: recent strategies for their detection and protection from inadvertent doping.
    Geyer H; Schänzer W; Thevis M
    Br J Sports Med; 2014 May; 48(10):820-6. PubMed ID: 24632537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive analysis of prohibited substances and methods in sports: Unveiling trends, pharmacokinetics, and WADA evolution.
    Oleksak P; Nepovimova E; Valko M; Alwasel S; Alomar S; Kuca K
    Environ Toxicol Pharmacol; 2024 Jun; 108():104447. PubMed ID: 38636744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current role of LC-MS(/MS) in doping control.
    Thevis M; Thomas A; Schänzer W
    Anal Bioanal Chem; 2011 Aug; 401(2):405-20. PubMed ID: 21424519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The list of prohibited substances and methods in sport: structure and review process by the world anti-doping agency.
    Mazzoni I; Barroso O; Rabin O
    J Anal Toxicol; 2011 Nov; 35(9):608-12. PubMed ID: 22080899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of prohibited substances by liquid chromatography tandem mass spectrometry for sports doping control.
    Ahrens BD; Starcevic B; Butch AW
    Methods Mol Biol; 2012; 902():115-28. PubMed ID: 22767112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doping and musculoskeletal system: short-term and long-lasting effects of doping agents.
    Nikolopoulos DD; Spiliopoulou C; Theocharis SE
    Fundam Clin Pharmacol; 2011 Oct; 25(5):535-63. PubMed ID: 21039821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.
    Thevis M; Schänzer W
    J Pharm Biomed Anal; 2014 Dec; 101():66-83. PubMed ID: 24906629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency and type of adverse analytical findings in athletics: Differences among disciplines.
    Aguilar-Navarro M; Salinero JJ; Muñoz-Guerra J; Plata MDM; Del Coso J
    Drug Test Anal; 2021 Aug; 13(8):1561-1568. PubMed ID: 33982423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Narrowing the gap between the number of athletes who dope and the number of athletes who are caught: scientific advances that increase the efficacy of antidoping tests.
    Botrè F; de la Torre X; Donati F; Mazzarino M
    Br J Sports Med; 2014 May; 48(10):833-6. PubMed ID: 24668049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls.
    Thevis M; Thomas A; Geyer H; Schänzer W
    Growth Horm IGF Res; 2014 Dec; 24(6):276-80. PubMed ID: 25466910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of legal and illegal stimulating agents in sports.
    Deventer K; Roels K; Delbeke FT; Van Eenoo P
    Anal Bioanal Chem; 2011 Aug; 401(2):421-32. PubMed ID: 21479548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.